-transparent.png){kind=logo}
Thymalfasin (thymosin-alpha1) is an immunomodulatory agent that is able to augment some specific T lymphocyte functions, particularly that of promoting the T helper 1 cell responses involved in host antiviral defence. The most promising clinical applications for thymalfasin seem to be as a single agent for the treatment of chronic hepatitis B and in combination with interferon-alpha for the treatment of both chronic hepatitis B and C. These positive preliminary results offer a strong rationale for larger, well-planned clinical trials and also for defining the optimal schedule of administration.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
A Gramenzi, and
C Cursaro, and
P Andreone, and
M Bernardi
July 2008,
Anaesthesia and intensive care,
A Gramenzi, and
C Cursaro, and
P Andreone, and
M Bernardi
February 1991,
Clinical cardiology,
A Gramenzi, and
C Cursaro, and
P Andreone, and
M Bernardi
January 2005,
Cardiovascular drug reviews,
A Gramenzi, and
C Cursaro, and
P Andreone, and
M Bernardi
January 2012,
Thrombosis,
A Gramenzi, and
C Cursaro, and
P Andreone, and
M Bernardi
December 1998,
Expert opinion on investigational drugs,
A Gramenzi, and
C Cursaro, and
P Andreone, and
M Bernardi
September 2010,
Molecular cancer therapeutics,
A Gramenzi, and
C Cursaro, and
P Andreone, and
M Bernardi
June 2014,
JACC. Cardiovascular interventions,
A Gramenzi, and
C Cursaro, and
P Andreone, and
M Bernardi
June 2021,
Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS,
A Gramenzi, and
C Cursaro, and
P Andreone, and
M Bernardi
April 1998,
Anaesthesia and intensive care,
A Gramenzi, and
C Cursaro, and
P Andreone, and
M Bernardi
January 1996,
The oncologist,
